MicroRNA‑206 inhibits the proliferation, migration and invasion of colorectal cancer cells by regulating the c‑Met/AKT/GSK‑3β pathway

Lyu,Jiayu; Sun,Yao; Li,Xizhi; Ma,Huili

doi:10.3892/ol.2020.12408

MicroRNA‑206 inhibits the proliferation, migration and invasion of colorectal cancer cells by regulating the c‑Met/AKT/GSK‑3β pathway

Authors:
- Jiayu Lyu
- Yao Sun
- Xizhi Li
- Huili Ma
View Affiliations

Affiliations: Department of First General Surgery, The Fifth Hospital of Harbin, Harbin, Heilongjiang 150040, P.R. China, Department of Neurology, General Hospital of Heilongjiang Province Land Reclamation Bureau, Harbin, Heilongjiang 150088, P.R. China, Department of Neurology, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China, Department of Emergency Surgical Trauma Center, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
Published online on: December 23, 2020 https://doi.org/10.3892/ol.2020.12408
Article Number: 147
Copyright: © Lyu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An imbalance in microRNA (miRNA/miR) expression is closely associated with tumorigenesis and progression. miR‑206 is downregulated in different types of tumors, including colorectal cancer (CRC). However, the effects of miR‑206 on the progression of CRC, and its underlying molecular mechanisms are yet to be elucidated. The present study aimed to investigate the effects of miR‑206 on the proliferation, migration and invasion of colorectal cancer cells, and determine its potential molecular mechanism. The results of the present study demonstrated that the expression levels of miR‑206 and c‑Met were affected in HCT116 and SW480 cells by transfected with miR‑206 mimic, inhibitor or small interfering RNA‑c‑Met. A dual‑luciferase reporter assay was performed to identify the miRNA targets. Cell proliferation, migration and invasion assays were also performed. The results demonstrated that overexpression of miR‑206 significantly decreased the viability of HCT116 and SW480 cells. The results of the Transwell assay indicated that the cell migratory and invasive abilities were inhibited following transfection with miR‑206 mimic. As a target of miR‑206, knockdown of c‑Met significantly suppressed cell viability, migration and invasion. In addition, c‑Met knockdown or overexpression of miR‑206 inhibited activation of the AKT/GSK‑3β pathway. Collectively, these results suggest that miR‑206 suppresses the proliferation, migration and invasion of CRC cells by targeting the c‑Met/AKT/GSK‑3β pathway.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zeng M, Zhu L, Li L and Kang C: miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett. 22:122017. View Article : Google Scholar : PubMed/NCBI
3	Wang B, Liu G, Ding L, Zhao J and Lu Y: FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer. Exp Ther Med. 16:133–140. 2018.PubMed/NCBI
4	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ma W, Liu B, Li J, Jiang J, Zhou R, Huang L, Li X, He X and Zhou Q: MicroRNA-302c represses epithelial-mesenchymal transition and metastasis by targeting transcription factor AP-4 in colorectal cancer. Biomed Pharmacother. 105:670–676. 2018. View Article : Google Scholar : PubMed/NCBI
6	Dou C, Liu Z, Xu M, Jia Y, Wang Y, Li Q, Yang W, Zheng X, Tu K and Liu Q: miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett. 381:380–390. 2016. View Article : Google Scholar : PubMed/NCBI
7	Tu K, Liu Z, Yao B, Han S and Yang W: MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974. 2016. View Article : Google Scholar : PubMed/NCBI
8	Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J and Lu J: MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells. Oncotarget. 7:24537–24548. 2016. View Article : Google Scholar : PubMed/NCBI
9	Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X, Wu J, Hu Z, Meng S, Liu B, et al: c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3beta/Snail signaling. Cell Death Dis. 7:e20882016. View Article : Google Scholar : PubMed/NCBI
10	Chen QY, Jiao DM, Yan L, Wu YQ, Hu HZ, Song J, Yan J, Wu LJ, Xu LQ and Shi JG: Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis. Mol Biosyst. 11:2290–2302. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96 Suppl:R40–R44. 2007.PubMed/NCBI
12	Ma G, Wang Y, Li Y, Cui L, Zhao Y, Zhao B and Li K: MiR-206, a key modulator of skeletal muscle development and disease. Int J Biol Sci. 11:345–352. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhu H, He G and Wang Y, Hu Y, Zhang Z, Qian X and Wang Y: Long intergenic noncoding RNA 00707 promotes colorectal cancer cell proliferation and metastasis by sponging miR-206. Onco Targets Ther. 12:4331–4340. 2019. View Article : Google Scholar : PubMed/NCBI
14	Zheng X, Ma YF, Zhang XR, Li Y, Zhao HH and Han SG: Circ_0056618 promoted cell proliferation, migration and angiogenesis through sponging with miR-206 and upregulating CXCR4 and VEGF-A in colorectal cancer. Eur Rev Med Pharmacol Sci. 24:4190–4202. 2020.PubMed/NCBI
15	Wang Y, Xu H, Si L, Li Q, Zhu X, Yu T and Gang X: MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate. 78:479–490. 2018. View Article : Google Scholar : PubMed/NCBI
16	Yang N, Wang L, Liu J, Liu L, Huang J, Chen X and Luo Z: MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2. Oncol Lett. 15:8295–8302. 2018.PubMed/NCBI
17	Liao M and Peng L: MiR-206 may suppress non-small lung cancer metastasis by targeting CORO1C. Cell Mol Biol Lett. 25:222020. View Article : Google Scholar : PubMed/NCBI
18	Fan C, Liu N, Zheng D, Du J and Wang K: MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1. Cancer Manag Res. 11:6755–6764. 2019. View Article : Google Scholar : PubMed/NCBI
19	Fu Y, Shao ZM, He QZ, Jiang BQ, Wu Y and Zhuang ZG: Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43. Eur Rev Med Pharmacol Sci. 19:2091–2104. 2015.PubMed/NCBI
20	Shengnan J, Dafei X, Hua J, Sunfu F, Xiaowei W and Liang X: Long non-coding RNA HOTAIR as a competitive endogenous RNA to sponge miR-206 to promote colorectal cancer progression by activating CCL2. J Cancer. 11:4431–4441. 2020. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
23	Pan JY, Sun CC, Bi ZY, Chen ZL, Li SJ, Li QQ, Wang YX, Bi YY and Li DJ: miR-206/133b cluster: A weapon against lung cancer? Mol Ther Nucleic Acids. 8:442–449. 2017. View Article : Google Scholar : PubMed/NCBI
24	Wang XW, Xi XQ, Wu J, Wan YY, Hui HX and Cao XF: MicroRNA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH3 in colorectal cancer. Oncol Rep. 33:1402–1410. 2015. View Article : Google Scholar : PubMed/NCBI
25	Liu X, Zheng W, Zhang X, Dong M and Sun G: The diagnostic and prognostic value of serum miR-206 in colorectal cancer. Int J Clin Exp Pathol. 10:7528–7533. 2017.PubMed/NCBI
26	Sun P, Sun D, Wang X, Liu T, Ma Z and Duan L: miR-206 is an independent prognostic factor and inhibits tumor invasion and migration in colorectal cancer. Cancer Biomark. 15:391–396. 2015. View Article : Google Scholar : PubMed/NCBI
27	Park YR, Seo SY, Kim SL, Zhu SM, Chun S, Oh JM, Lee MR, Kim SH, Kim IH, Lee SO, et al: MiRNA-206 suppresses PGE2-induced colorectal cancer cell proliferation, migration, and invasion by targetting TM4SF1. Biosci Rep. 38:BSR201806642018. View Article : Google Scholar : PubMed/NCBI
28	Meng X and Fu R: miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther. 11:1757–1765. 2018. View Article : Google Scholar : PubMed/NCBI
29	Ren XL, He GY, Li XM, Men H, Yi LZ, Lu GF, Xin SN, Wu PX, Li YL, Liao WT, et al: MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2. J Cancer Res Clin Oncol. 142:581–592. 2016. View Article : Google Scholar : PubMed/NCBI
30	Dai C, Xie Y, Zhuang X and Yuan Z: MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomed Pharmacother. 104:763–770. 2018. View Article : Google Scholar : PubMed/NCBI
31	Mataki H, Seki N, Chiyomaru T, Enokida H, Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M and Inoue H: Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. Int J Oncol. 46:1039–1050. 2015. View Article : Google Scholar : PubMed/NCBI
32	Chen X, Tong ZK and Zhou JY, Yao YK, Zhang SM and Zhou JY: MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET. Oncol Lett. 12:1171–1177. 2016. View Article : Google Scholar : PubMed/NCBI
33	Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R and Hong D: Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 66:95–103. 2018. View Article : Google Scholar : PubMed/NCBI
34	Zhao Y, Tao Q, Li S, Zheng P, Liu J and Liang X: Both endogenous and exogenous miR-139-5p inhibit Fusobacterium nucleatum-related colorectal cancer development. Eur J Pharmacol. 888:1734592020. View Article : Google Scholar : PubMed/NCBI
35	Liao H, Ahmed M, Markezana A, Zeng G, Stechele M, Galun E and Goldberg SN: Thermal ablation induces transitory metastatic growth by means of the STAT3/c-Met molecular pathway in an intrahepatic colorectal cancer mouse model. Radiology. 294:464–472. 2020. View Article : Google Scholar : PubMed/NCBI
36	Yao JF, Li XJ, Yan LK, He S, Zheng JB, Wang XR, Zhou PH, Zhang L, Wei GB and Sun XJ: Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis. J Biochem Mol Toxicol. 33:e223162019. View Article : Google Scholar : PubMed/NCBI
37	Xu Z, Zhu C, Chen C, Zong Y, Feng H, Liu D, Feng W, Zhao J and Lu A: CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer. Cell Death Dis. 9:9742018. View Article : Google Scholar : PubMed/NCBI
38	Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
39	Viticchiè G and Muller PAJ: c-Met and other cell surface molecules: Interaction, activation and functional consequences. Biomedicines. 3:46–70. 2015. View Article : Google Scholar : PubMed/NCBI
40	Yamaoka T, Kusumoto S, Ando K, Ohba M and Ohmori T: Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 19:34912018. View Article : Google Scholar
41	Organ SL and Tsao MS: An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 3 (Suppl 1):S7–S19. 2011. View Article : Google Scholar : PubMed/NCBI
42	Comoglio PM, Trusolino L and Boccaccio C: Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy. Nat Rev Cancer. 18:341–358. 2018. View Article : Google Scholar : PubMed/NCBI
43	Lu Z, Song N, Shen B, Xu X, Fang Y, Shi Y, Ning Y, Hu J, Dai Y, Ding X, et al: Syndecan-1 shedding inhibition to protect against ischemic acute kidney injury through HGF target signaling pathway. Transplantation. 102:e331–e344. 2018. View Article : Google Scholar : PubMed/NCBI